Sarah leonard
Chief Executive Officer T-Cypher Bio
Sarah is an experienced immunologist with a track record of advancing novel T cell therapeutics from concept to clinic. Before building the scientific team at T-Cypher, she was a Scientist in Residence at Oxford Science Enterprises, creating innovative life science ventures. Prior to this Sarah was at Immunocore leading a team to generate novel donor-unrestricted T cell therapeutics, as well as contributing to the successful delivery of HBV-bispecifics to clinical trials. Prior to Immunocore, Sarah held a Translational Research Fellowship with Ovacome for ovarian cancer therapeutics and worked with Janssen Pharmaceuticals delivering a pre-clinical package for a drug combination that went into an acute myeloid leukaemia clinical trial.
Seminars
- Novel approach to T-cell engagers against intracellular targets: T-Cypher uses TCR-based bispecifics to target intracellular cancer antigens that conventional therapies can’t reach
- Proprietary AI discovery platform: An internally-developed engine rapidly identifies and optimises high-affinity TCRs with exceptional safety profiles
- Two lead programs moving toward the clinic: Advanced pipeline with near-term IND filings and clear clinical development timelines
